Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

141. Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia Full Text available with Trip Pro

Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Targeting social and non-social cognition to improve cognitive remediation outcomes in schizophrenia Article Text Psychological interventions Targeting social and non-social cognition

2016 Evidence-Based Mental Health

142. Alpha-7 nicotinic agonist improves cognition in schizophrenia

Alpha-7 nicotinic agonist improves cognition in schizophrenia Alpha-7 nicotinic agonist improves cognition in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Alpha-7 nicotinic agonist improves cognition in schizophrenia Article Text Pharmacological interventions Alpha-7 nicotinic agonist improves cognition in schizophrenia Stephen R. Marder Statistics from Altmetric.com ABSTRACT FROM: Keefe RS, Meltzer HA, Dgetluck N

2016 Evidence-Based Mental Health

143. Pharmacological interventions: Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia?

Pharmacological interventions: Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? Article Text Electronic pages Pharmacological interventions Which

2016 Evidence-Based Mental Health

144. Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis

Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis Article Text Pharmacological interventions Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis Taro Kishi Statistics from Altmetric.com ABSTRACT FROM: Samara MT, Leucht C, Leeflang MM, et al . Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J

2016 Evidence-Based Mental Health

145. Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders Full Text available with Trip Pro

Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders Article Text Causes and risk

2016 Evidence-Based Mental Health

146. Diagnostic Accuracy of Brain-derived Neurotrophic Factor and Nitric Oxide in Patients with Schizophrenia: A pilot study Full Text available with Trip Pro

Diagnostic Accuracy of Brain-derived Neurotrophic Factor and Nitric Oxide in Patients with Schizophrenia: A pilot study Brain-derived neurotrophic factor (BDNF) and nitric oxide (NO) play multiple roles in the developing and adult CNS. Since BDNF and NO metabolisms are dysregulated in schizophrenia, we measured these markers simultaneously in the blood of schizophrenics and assessed their diagnostic accuracy.Thirty-eight patients with schizophrenia classified according to demographic (...) good diagnostic accuracy, but BDNF had better ROC curve characteristics, especially in patients with negative symptomatology.BDNF and nitrite/nitrate showed inverse changes in schizophrenic patients. The most pronounced changes were found in patients treated with second-generation antipsychotics. Although BDNF is not specific of schizophrenia, it may be a clinically useful biomarker for the diagnosis of patients expressing predominantly negative symptoms.

2015 Journal of medical biochemistry

147. [Group psychoeducational intervention in relatives of patients suffering from schizophrenia]. (Abstract)

[Group psychoeducational intervention in relatives of patients suffering from schizophrenia]. The present research paper aims at assessing the effectiveness of a psychoeducational intervention in relatives' groups of patients with schizophrenia or schizoaffective disorder. It examines the possible influence of the intervention on family members as well as on the course of the patient illness. Of a total of 131 relatives, 83 consisted the experimental group and 48 the control group

2015 Psychiatrike = Psychiatriki

148. Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review

]. 2006 Feb 2 [cited 2010 Jun 25];354(5):472-82. Available from: Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005 Jan;66(1):63-72. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive (...) ):274-85. Kelly DL, Richardson CM, Yu Y, Conley RR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol. 2006 Aug;21(6):393-8. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52-63. Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, et al. Prolactin levels in schizophrenia

2015 CADTH - Health Technology Assessment

149. Lithium for schizophrenia. Full Text available with Trip Pro

Lithium for schizophrenia. Many people with schizophrenia do not achieve a satisfactory treatment response with ordinary anti-psychotic drug treatment. In these cases, various add-on medications are used, among them lithium.To assess whether:1. Lithium alone is an effective treatment for schizophrenia, schizophrenia-like psychoses and schizoaffective psychoses; and2. Lithium augmentation of antipsychotic medication is an effective treatment for the same illnesses.In July 2012, we searched (...) the Cochrane Schizophrenia Group's Study-Based Register of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. This search was updated on January 20, 2015. For the first version of the review, we also contacted pharmaceutical companies and authors of relevant studies to identify further trials and obtain original participant data.Randomised controlled trials (RCTs) of lithium compared with antipsychotics or placebo

2015 Cochrane

150. Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. Full Text available with Trip Pro

Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. Cognitive behavioural therapy for people with schizophrenia is a psychotherapeutic approach that establishes links between thoughts, emotions and behaviours and challenges dysfunctional thoughts. There is some evidence to suggest that cognitive behavioural therapy for people with psychosis (CBTp) might be an effective treatment for people with schizophrenia. There are however, limitations in its provision due (...) to available resource and training issues. One way to tackle this issue might be to offer a brief version of CBTp.To review the effects of brief CBTp (6 to 10 regular sessions given in less than 4 months and using a manual) for people with schizophrenia compared with standard CBTp (12 to 20 regular sessions given in 4 to 6 months and using a manual).We searched the Cochrane Schizophrenia Group's Trials Register (August 21, 2013 and August 26, 2015) which is based on regular searches of CINAHL, BIOSIS, AMED

2015 Cochrane

151. Yoga versus standard care for schizophrenia. (Abstract)

Yoga versus standard care for schizophrenia. Yoga is an ancient spiritual practice that originated in India and is currently accepted in the Western world as a form of relaxation and exercise. It has been of interest for people with schizophrenia to determine its efficacy as an adjunct to standard-care treatment.To examine the effects of yoga versus standard care for people with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (November 2012 and January 29, 2015 (...) ), which is based on regular searches of MEDLINE, PubMed, EMBASE, CINAHL, BIOSIS, AMED, PsycINFO, and registries of clinical trials. We searched the references of all included studies. There were no language, date, document type, or publication status limitations for inclusion of records in the register.All randomised controlled trials (RCTs) including people with schizophrenia comparing yoga to standard-care control.The review team independently selected studies, quality rated these, and extracted

2015 Cochrane

152. The effectiveness of compliance therapy on drug attitude among schizophrenic patients: a systematic review. (Abstract)

The effectiveness of compliance therapy on drug attitude among schizophrenic patients: a systematic review. Schizophrenia is one of the most severe mental illnesses. Studies have found that 25% to 80% of all schizophrenic patients are non-compliant in medication-taking. Non-compliance of medication-taking is associated with higher readmission rates that result from relapses. Compliance therapy has been developed to modify negative beliefs toward medication and aims to improve drug attitude (...) toward medication-taking. However, the effect of compliance therapy on drug attitude among schizophrenic patients is unclear.The objective of this review was to systematically review the available evidence with regards to the effect of compliance therapy on improving attitudes toward medication among schizophrenic patients.People diagnosed with schizophrenia, schizophrenia-form disorder, delusion disorder, schizo-affective disorder. TYPES OF INTERVENTION(S): The review considered studies

2015 JBI database of systematic reviews and implementation reports

153. Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses

Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses | CADTH.ca Find the information you need Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Published on: December 15, 2011 Project Number: HO503 Product Line: Result type: Report The Canadian Agency for Drugs and Technologies in Health (...) (CADTH) has undertaken an optimal use project to assess the clinical and economic impact of using atypical antipsychotic combination therapy, as well as high-dosing treatment strategies, in adolescents and adults with schizophrenia. The current project has several key components: Appraise the clinical and cost-effectiveness of combination and high-dose therapy with atypical antipsychotic agents for the treatment of schizophrenia Develop optimal use recommendations or advice Identify gaps in current

2015 CADTH - Optimal Use

154. Transcranial magnetic stimulation (TMS) for schizophrenia. Full Text available with Trip Pro

Transcranial magnetic stimulation (TMS) for schizophrenia. People with schizophrenia often experience symptoms which fail to fully respond to antipsychotic medication. Transcranial magnetic stimulation (TMS) has been proposed as a new treatment for people with schizophrenia, especially those who experience persistent auditory hallucinations.To estimate the effects of TMS alone, compared with sham TMS or with 'standard management' and any other comparison interventions in reducing psychotic (...) symptoms associated with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (June 2006, June 2008, April 2013). This register is compiled by methodical searches of MEDLINE, EMBASE, BIOSIS, CINAHL, Dissertation abstracts, LILACS, PSYNDEX, PsycINFO, RUSSMED, and Sociofile, and is supplemented with handsearching of relevant journals and numerous conference proceedings.We included all randomised controlled trials recruiting at least five participants and comparing TMS with sham TMS

2015 Cochrane

155. Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis. Full Text available with Trip Pro

Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis. Schizophrenia is a psychiatric disorder which involves distortions in thought and perception, blunted affect, and behavioural disturbances. The longer psychosis goes unnoticed and untreated, the more severe the repercussions for relapse and recovery. There is some evidence that early intervention services can help, and diagnostic techniques that could contribute to early (...) an individual will progress on to developing schizophrenia as opposed to other types of psychosis.To determine whether VBM applied to the brain can be used to differentiate schizophrenia from other types of psychosis in participants who have received a clinical diagnosis of first episode psychosis.In December 2013, we updated a previous search (May 2012) of MEDLINE, EMBASE, and PsycInfo using OvidSP.We included retrospective and prospective studies that consecutively or randomly selected adolescent

2015 Cochrane

156. Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review

]. 2006 Feb 2 [cited 2010 Jun 25];354(5):472-82. Available from: Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005 Jan;66(1):63-72. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive (...) ):274-85. Kelly DL, Richardson CM, Yu Y, Conley RR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol. 2006 Aug;21(6):393-8. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52-63. Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, et al. Prolactin levels in schizophrenia

2015 CADTH - Health Technology Assessment

157. Social skills programmes for schizophrenia. Full Text available with Trip Pro

Social skills programmes for schizophrenia. Social skills programmes (SSP) are treatment strategies aimed at enhancing the social performance and reducing the distress and difficulty experienced by people with a diagnosis of schizophrenia and can be incorporated as part of the rehabilitation package for people with schizophrenia.The primary objective is to investigate the effects of social skills training programmes, compared to standard care, for people with schizophrenia.We searched (...) the Cochrane Schizophrenia Group's Trials Register (November 2006 and December 2011) which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. We inspected references of all identified studies for further trials.A further search for studies has been conducted by the Cochrane Schizophrenia Group in 2015, 37 citations have been found and are currently being assessed by review authors.We included all relevant randomised controlled trials

2015 Cochrane

158. [Attributable risk of co-morbid substance use disorder in poor observance to pharmacological treatment and the occurrence of relapse in schizophrenia]. (Abstract)

[Attributable risk of co-morbid substance use disorder in poor observance to pharmacological treatment and the occurrence of relapse in schizophrenia]. There are numerous risk factors involved in poor (incomplete) compliance to pharmacological treatment, and the associated relapse risk, for patients with schizophrenia. Comorbid substance use disorders are considered as among the most important ones, although how much their presence increase the risk of poorer observance (and higher risk (...) ) AND schizophrenia AND (French OR English [Language])" and "(Substance Abuse OR substance dependance) AND Outcome AND schizophrenia AND (French OR English [Language])". Studies were included if they describe two patients groups (schizophrenia with and without present substance use disorder) and assess the studied outcome. MetaWin(®) version 2 was used for the meta-analysis, while publication time bias relied on non-parametric correlation and the one linked to sample size was assessed through normal quantile

2015 L'Encephale

159. Supportive therapy for schizophrenia. Full Text available with Trip Pro

Supportive therapy for schizophrenia. Supportive therapy is often used in everyday clinical care and in evaluative studies of other treatments.To review the effects of supportive therapy compared with standard care, or other treatments in addition to standard care for people with schizophrenia.For this update, we searched the Cochrane Schizophrenia Group's register of trials (November 2012).All randomised trials involving people with schizophrenia and comparing supportive therapy with any other

2015 Cochrane

160. Lurasidone (Latuda) - schizophrenia

Lurasidone (Latuda) - schizophrenia Final Appraisal Recommendation Advice No: 0115 – February 2015 Lurasidone (Latuda ® ? ) 18.5 mg, 37 mg and 74 mg film-coated tablets Submission by Sunovion Pharmaceuticals Europe Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1142), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant (...) being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0115: Lurasidone (Latuda ® ? ) 18.5 mg, 37 mg and 74 mg film-coated tablets. February 2015. Recommendation of AWMSG Lurasidone (Latuda ® ? ) is recommended as an option for use within NHS Wales for the treatment of schizophrenia in adults aged 18 years and over.

2015 All Wales Medicines Strategy Group